KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Equity Average (2018 - 2025)

Historic Equity Average for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Q3 2025 value amounting to -$111.2 million.

  • Amneal Pharmaceuticals' Equity Average fell 4728.84% to -$111.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$111.2 million, marking a year-over-year decrease of 4728.84%. This contributed to the annual value of -$44.8 million for FY2024, which is 14387.52% down from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Equity Average stood at -$111.2 million, which was down 4728.84% from -$122.3 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Equity Average peaked at $387.2 million during Q1 2022, and registered a low of -$122.3 million during Q2 2025.
  • For the 5-year period, Amneal Pharmaceuticals' Equity Average averaged around $130.2 million, with its median value being $152.5 million (2023).
  • In the last 5 years, Amneal Pharmaceuticals' Equity Average surged by 881.63% in 2022 and then crashed by 45369.8% in 2025.
  • Amneal Pharmaceuticals' Equity Average (Quarter) stood at $375.1 million in 2021, then crashed by 49.57% to $189.1 million in 2022, then crashed by 53.94% to $87.1 million in 2023, then plummeted by 216.55% to -$101.5 million in 2024, then dropped by 9.56% to -$111.2 million in 2025.
  • Its last three reported values are -$111.2 million in Q3 2025, -$122.3 million for Q2 2025, and -$120.8 million during Q1 2025.